| Literature DB >> 29414779 |
Jenny Sandmark1, Göran Dahl1, Linda Öster1, Bingze Xu2,3, Patrik Johansson1, Tomas Akerud1, Anna Aagaard1, Pia Davidsson4, Janna M Bigalke1, Maria Sörhede Winzell4, G Jonah Rainey5, Robert G Roth6.
Abstract
Neurturin (NRTN) provides trophic support to neurons and is considered a therapeutic agent for neurodegenerative diseases, such as Parkinson's disease. It binds to its co-receptor GFRa2, and the resulting NRTN-GFRa2 complex activates the transmembrane receptors rearranged during transfection (RET) or the neural cell adhesion molecule (NCAM). We report the crystal structure of NRTN, alone and in complex with GFRa2. This is the first crystal structure of a GFRa with all three domains and shows that domain 1 does not interact directly with NRTN, but it may support an interaction with RET and/or NCAM, via a highly conserved surface. In addition, biophysical results show that the relative concentration of GFRa2 on cell surfaces can affect the functional affinity of NRTN through avidity effects. We have identified a heparan sulfate-binding site on NRTN and a putative binding site in GFRa2, suggesting that heparan sulfate has a role in the assembly of the signaling complex. We further show that mutant NRTN with reduced affinity for heparan sulfate may provide a route forward for delivery of NRTN with increased exposure in preclinical in vivo models and ultimately to Parkinson's patients.Entities:
Keywords: GDNF; GFRa; RET; avidity; cell signaling; crystallography; glial cell-derived neurotrophic factor; heparan sulfate; heparin; surface plasmon resonance (SPR)
Mesh:
Substances:
Year: 2018 PMID: 29414779 PMCID: PMC5900780 DOI: 10.1074/jbc.RA117.000820
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157